Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit-Reference-Cited by-同舟云学术

Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit

Published:2024-04-27 Issue:7 Volume:43 Page:1453-1459
ISSN:0934-9723
Container-title:European Journal of Clinical Microbiology & Infectious Diseases
language:en
Short-container-title:Eur J Clin Microbiol Infect Dis

Author:

Dudoignon Emmanuel,Caméléna Francois,Lafaurie Matthieu,Deniau Benjamin,Chaussard Maité,Coutrot Maxime,Guillemet Lucie,Cupaciu Alexandru,Pharaboz Alexandre,Boutin Louis,Benyamina Mourad,Chaouat Marc,Mimoun Maurice,Merimèche Manel,Mebazaa Alexandre,Plaud Benoit,Berçot Béatrice,Dépret François,Mellon Guillaume

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10096-024-04840-9.pdf

Reference15 articles.

1. Teng J, Imani S, Zhou A, Zhao Y, Du L, Deng S et al (2023) Combatting resistance: understanding multi-drug resistant pathogens in intensive care units. Biomed Pharmacother Biomedecine Pharmacother 167:115564. https://doi.org/10.1016/j.biopha.2023.115564

2. Munier AL, Biard L, Legrand M, Rousseau C, Lafaurie M, Donay JL et al (2019) Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. Int J Infect Dis IJID off Publ Int Soc Infect Dis 79:179–184. https://doi.org/10.1016/j.ijid.2018.11.371

3. Corcione S, Lupia T, De Rosa FG, Host and Microbiota Interaction Study Group (ESGHAMI) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (2020) Microbiome in the setting of burn patients: implications for infections and clinical outcomes. Burns Trauma 8:tkaa033. https://doi.org/10.1093/burnst/tkaa033

4. Parsels KA, Mastro KA, Steele JM, Thomas SJ, Kufel WD (2021) Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother 76(6):1379–1391. https://doi.org/10.1093/jac/dkab015

5. Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226–240. https://doi.org/10.1016/S1473-3099(20)30796-9